Ardigen at AACR Special Conference Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer

Topic:

Between October 14th and 17th our lead scientist Giovanni Mazzocco attended the 30th Anniversary AACR Special Conference.

The conference titled “Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer” was focused on discussing the power and limitations of computational tools for the analysis of cancer related data.

During those four days we attended sessions, talked to speakers and exhibitors, discussed posters and deepend our knowledge on the intersection between cancer research and data science. This conference gave us the opportunity to hear about the state of the art of cancer research from incident to early diagnosis, prevention, treatment and outcome prediction, with great emphasis on approaches leveraging big data and new computational methods such as machine learning and artificial intelligence.

Please have a look at our blog to read more about our impressions from the meeting.

You might be also interested in:

Illustration of agentic AI in drug discovery connecting computational analysis with laboratory experiments.
How Agentic AI is closing the loop in drug discovery
Ardigen phenAID platform
AI Phenotypic Profiling for Hit Prioritization
biology binder design case study
AI Protein Binder Design Case Study
scientist working on the target identification case study
AI Target Discovery from Multimodal Data

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!